Thomas Frank is facing what could be a defining period of his Tottenham Hotspur career just six months into his time as head ...
Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the closing of the $25M final tranche to its Series B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback